Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

New patents provide additional composition of matter and methods of use claims for Enveric’s EVM301 series neuroplastogenic molecules, and recently out-licensed tryptamine-derived prodrugs, including EB-002, a new chemical entity psilocin prodrug

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 12,133,856 (the ‘856 patent) and 12,138,276,(the ‘276 patent) bringing the total number of issued patents supporting its EVM301 series molecules to 11. The claims of the ‘856 patent and the ‘276 patent expand the range of protection for novel, non-obvious multi-substituent and halogenated psilocybin derivative compounds and pharmaceutical formulations containing such compounds, respectively.

Enveric’s EB-003 compound emerged as Enveric’s lead candidate from its EVM301 series of molecules and was generated from its molecular library, Psybrary™, a proprietary catalogue of over 1,000 tryptamine derivatives that incorporates receptor engagement and functional data to correlate structure with biological activity. EB-003 is intended to target anxiety, depression, and addiction disorders. Recent announcements have highlighted the promising pre-clinical data demonstrating the potential for the EB-003 compound to promote neuroplasticity and be orally administered at doses believed to be efficacious without hallucinogenic effect, both of which we believe to be key criteria of commercial and regulatory interest.

In addition, Enveric announced that the USPTO has issued two other U.S. Patents, No. 12,065,404 (the ‘404 patent) and 12,077,498 (the ’498 patent), related to its EVM201 series prodrug molecules. The claims of the ‘404 patent and ‘498 patent protect novel, non-obvious C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical drug formulations containing such compounds, and methods of making such compounds, respectively. These compounds are prodrugs intended to treat neurological disorders. Enveric recently announced that it licensed its EVM201 Series to MycoMedica Life Sciences (MycoMedica). These additional patents strengthen and underscore the potential value to Enveric and MycoMedica, which plans to develop the lead EVM201 Series compound EB-002.

“These patent issuances from the USPTO add important pillars to Enveric’s intellectual property portfolio as we continue to distinguish the pre-clinical performance of our tryptamine-based molecules under development for the treatment of mental health disorders from others on the market or under development,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Importantly, with our focus squarely on our EVM301 Series, we expect to continue uncovering positive data highlighting the promising properties of EB-003, which is designed to capitalize on the potential for inducing neuroplasticity without causing hallucinations that can meet key commercial and regulatory criteria to advance to clinical trials.”

Enveric has announced out-licensing deals with MycoMedica and Aries Science & Technology, which positions Enveric to focus its resources on development of its lead compound EB-003. These deals establish potential future income streams to support the development and commercialization of Enveric’s pipeline candidates.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

Contacts

Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected]

Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 [email protected]